Search alternatives:
ms decrease » _ decrease (Expand Search), use decreased (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ms » 50 mg (Expand Search), 50 mm (Expand Search)
19 a » 19 _ (Expand Search), 19 p (Expand Search)
Showing 21 - 40 results of 31,988 for search '(( 50 ms decrease ) OR ((( 5 ((nn decrease) OR (mean decrease)) ) OR ( 19 a decrease ))))', query time: 0.73s Refine Results
  1. 21
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 22
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 23
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 24
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 25
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 26
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 27
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 28
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 29
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 30
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 31
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 32
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 33
    HVR1-swap compensatory E1/E2 substitutions typically decrease virus entry dependency on SR-BI.

    HVR1-swap compensatory E1/E2 substitutions typically decrease virus entry dependency on SR-BI. by Christina Holmboe Olesen (11154333)

    Published 2021
    Save to List
    Saved in:
  14. 34
    RNF5 loss decreases PEL xenograft tumor growth and cell cycle gene expression.

    RNF5 loss decreases PEL xenograft tumor growth and cell cycle gene expression. by Xiaojuan Li (351842)

    Published 2023
    Save to List
    Saved in:
  15. 35
    Table_1_Risk of psychological distress by decrease in economic activity, gender, and age due to COVID-19: A multinational study.DOCX

    Table_1_Risk of psychological distress by decrease in economic activity, gender, and age due to COVID-19: A multinational study.DOCX by Minji Kim (1722313)

    Published 2023
    “…</p>Discussion<p>Psychological distress due to COVID-19 revealed a significant association with decrease in economic activity, women, and younger age. …”
    Save to List
    Saved in:
  16. 36
    A T-test mean comparison of pre and post COVID-19 differences for selected variables.

    A T-test mean comparison of pre and post COVID-19 differences for selected variables. by Beshir Bedru Nasir (8218863)

    Published 2024
    Save to List
    Saved in:
  17. 37
    Comparison of mean differences in temperature decreases.

    Comparison of mean differences in temperature decreases. by Hans-Jörg Gillmann (8460585)

    Published 2022
    Save to List
    Saved in:
  18. 38
    Decreasing mean transistor size since 2000.

    Decreasing mean transistor size since 2000. by David Burg (8209752)

    Published 2021
    Save to List
    Saved in:
  19. 39
    Mean value of ENSS and subscales.

    Mean value of ENSS and subscales. by Phu Dinh Vu (19429477)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 40
    TPP decreases melanoma tumor growth rate when administered via hydrogel.

    TPP decreases melanoma tumor growth rate when administered via hydrogel. by Kyle C. Kloepping (9928265)

    Published 2020
    Save to List
    Saved in:

Search Tools: